Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mirae Asset Capital Life Science is a U.S.-based venture capital affiliate of the global financial conglomerate Mirae Asset Financial Group. Launched in 2023 with an inaugural $50 million fund ("Inception I"), it focuses on investing in private biotechnology companies developing therapeutics—primarily in oncology and other major disease areas—from seed through Series C stages. The firm is modality agnostic and also considers investments in diagnostics and AI/ML tools for drug discovery. It has already led significant rounds such as a $75 million Series C for an oncology company pioneering small molecule precision therapies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mirae Asset.